Healthcare communication company Conversa Health revealed on Tuesday that it has appointed a new chief technology officer, Cameron Ough.
In his new role, Ough is expected to be a key leader in the continued development and implementation of a comprehensive business strategy to address opportunities in the Provider, Payer and Pharma markets. The company said Ough will establish and grow its technology roadmap and lead all the technical initiatives, focusing on customer/end-user satisfaction and value metrics for clients and partners.
Ough previously worked at Cigna for ten years, where he served as a senior director in IT, with responsibility for Clinical Data Interoperability and Consumer & Digital Health.
Earlier, Ough spent ten years at Intel in several technology initiatives as an engineering and architecture lead. He reportedly pioneered projects that included data centre management capabilities, product and service localisation. He was also the solution lead for Intel Digital Health's Remote Care Management platform.
Conversa is an intelligent, automated conversation platform for healthcare. The company has an extensive library of over 700+ clinically-intelligent conversation programs that include asthma, chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF), diabetes, hypertension, and joint replacement. With its innovative and scalable Conversational AI technology, Conversa said healthcare organizations can deliver automated, personalized doctor-patient conversation experiences that lead to more meaningful patient relationships, effective population management and, ultimately, better clinical and financial outcomes.
POLYTECH Health & Aesthetics announces Poland expansion
Santhera Pharmaceuticals signs Gulf region distribution agreement with Uniphar
Novo Nordisk expands legal action over compounded 'semaglutide'
Neuraxpharm launches Neuraxpharm Australia
OncoZenge selects Meribel Pharma as CDMO for Phase 3 BupiZenge project
Fridays nominated for World Out of Home awards for weight loss campaign
Physiomics expands into biometrics with two contract wins and new division head
DELFI Diagnostics CTO receives 2025 Most Influential Women in Bay Area Business recognition
Clario acquires imaging provider NeuroRx
Healthcare Holding Schweiz AG acquires Effectum CH-Rep AG to expand services
iOncologi acquires TargImmune Therapeutics
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval